Sean Whooley
Sean Whooley covers how money, strategy and regulation move through the medical device industry, focusing on the deals, earnings and approvals that shift the outlook for major device makers and their partners. He reports business news for MassDevice with an emphasis on concrete numbers, transaction terms and what they mean for company portfolios and market position.
Business-side coverage of medical devices
Whooley’s core subject is the business performance of device manufacturers, from large multinationals to high-growth specialists. His stories track revenue trends, segment growth and changes in guidance, with clear attention to which product lines or geographies drive the numbers. He covers capital allocation decisions such as investments, acquisitions and share repurchase plans, treating them as signals of how medtech leaders manage their balance sheets and bet on future technology.
He works across cardiovascular, orthopedics, neurotechnology, diabetes technology and surgical robotics rather than staying inside a single clinical silo. Company names, product families and device categories are treated as business units as much as therapies, and he writes in a way that lets readers situate each move inside the broader competitive landscape. Financial terms, timelines and stated strategic rationales are foregrounded, with clinical and technical detail included as needed to explain commercial stakes rather than for its own sake.
Deals, investments and portfolio strategy
A recurring strand in Whooley’s coverage is the structure and intent of medtech deals. He reports on equity investments, takeovers, joint ventures and licensing agreements, highlighting upfront payments, milestone structures, equity percentages and total deal values where disclosed.
In stories such as Boston Scientific’s multibillion-dollar investment in TAVR developer MiRus paired with a large share repurchase plan, he treats a single news day as a window into both external growth strategy and internal capital return priorities.
He consistently frames transactions in terms of portfolio fit: which therapeutic area a target strengthens, how a new platform complements or disrupts an incumbent franchise, and whether the move extends a company into adjacent procedures or care settings. Emerging companies and technologies are introduced in that strategic context, with enough technical description to show why an incumbent is backing them and how the technology could scale commercially. His deal reporting helps readers see medtech not just as a pipeline of devices but as a set of evolving asset portfolios.
Earnings, guidance and market signals
Whooley also builds a steady record of earnings coverage for publicly traded device makers. His articles break out quarterly revenue, earnings per share, year-over-year growth and margin trends, calling out beats and misses against expectations when those are central to the story.
He reports on management commentary around demand, supply chain, pricing, procedure volumes and R&D spending, showing how executives explain both short-term fluctuations and long-term bets.
Guidance changes, cost-cutting programs and restructuring plans are treated as important news in their own right, not as footnotes. He connects these moves to product launches, regulatory milestones and clinical data readouts when they influence the outlook for key franchises. Stock market reaction, when included, sits alongside operational detail rather than replacing it; the focus stays on what the numbers mean for business momentum and the ability to fund innovation.
Regulatory milestones and clinical data through a commercial lens
Regulatory clearances, approvals and key clinical trial results enter Whooley’s feed when they carry clear business implications. He covers FDA decisions, CE marks and other regulatory milestones with attention to label scope, indications, patient populations and any notable conditions that affect commercialization. Device performance data and trial outcomes are summarized in accessible terms, then tied directly to questions of reimbursement, adoption and competitive positioning.
Across this work, his distinguishing trait is consistency in treating clinical and regulatory news as part of a commercial story: how fast a device can reach market, how broadly it can be used and how it might reshape revenue mix for the companies involved. The result is coverage that serves readers who follow medtech as an industry and a business, not only as a set of technologies.
4 more business journalists.
Aaron Karp
Aaron Karp is distinct for connecting airline networks, airport infrastructure, air cargo and policy. He is a senior editor at Air Transport World and has covered aviation since 1999. He has also worked as an editor for cargo-focused and daily aviation publications. His real beat is how airlines and airports respond to growth, regulation, trade conditions, sustainability pressures and technology changes. He covers route planning, network development, airport capacity, infrastructure, cargo flows, trade lanes, safety, air traffic control and future technology. He reports through news, features, opinion pieces, briefings and podcasts. He uses data, executive insight and industry conference reporting to explain market changes. His work links cargo metrics and trade policy to carrier strategy, and connects infrastructure and sustainability decisions to resilience, costs and long-term growth.
Adrienne Roberts
Adrienne Roberts is a business journalist at the Detroit Free Press who covers how policy, regulation and corporate decisions affect Michigan’s cannabis market, jobs, universities and health systems. She has a sustained focus on cannabis taxes, licensing, sales, product rules, consumer safety and local tax revenue. She also reports on unemployment, worker protections, corporate settlements, hiring, higher education, student safety, housing, data centers, health care access and economic forecasts. Roberts joined the Detroit Free Press in 2020 after covering automotive retail, dealers and labor issues for The Wall Street Journal. She explains complex business and regulatory changes with data, legal detail and on-the-ground voices. Her stories focus on practical effects for workers, students, consumers and communities, showing both the numbers and the people behind them.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex DeMarban
Alex DeMarban stands out for tracking major energy projects over time while showing how economic shifts affect local businesses. He reports for the Anchorage Daily News on business, oil and gas, and general assignments. His coverage focuses on Alaska LNG, long-haul energy projects, mining, ports, transportation infrastructure, and the everyday businesses that keep the state running. He examines financing, tax legislation, labor agreements, regulatory approvals, timelines and costs, and connects government and corporate decisions to workers, communities and consumers. He also reports on restaurant closures, grocery stores, breweries, meaderies, parking and trade disputes. His past coverage includes an open-pit mine near the proposed Ambler road, federal port grants and competitive elections. He reports through dollar figures, project details, public records, business owners and affected workers, showing how policy and resource development play out on the ground.